loading page

Atlantic DIP: Is weight gain less than that recommended by IOM safe in obese women with Gestational Diabetes Mellitus? – a retrospective study
  • +2
  • Delia Bogdanet,
  • Mohamad Mustafa,
  • Aftab Khattak,
  • Paula O'Shea,
  • Fidelma Dunne
Delia Bogdanet
National University of Ireland Galway College of Medicine Nursing and Health Sciences
Author Profile
Mohamad Mustafa
University Hospital Galway
Author Profile
Aftab Khattak
University Hospital Galway
Author Profile
Paula O'Shea
Galway University Hospitals
Author Profile
Fidelma Dunne
National University of Ireland Galway College of Medicine Nursing and Health Sciences
Author Profile

Abstract

Objective The study objective was to examine maternal and infant outcomes for obese GDM women who lost weight or gained 0-5 kg during pregnancy. Design A 7-year retrospective study of pregnancy outcomes for obese GDM women. Setting The ATLANTIC DIP consists of 5 antenatal centres along the Irish Atlantic seaboard. Population A total of 754 women met the inclusion criteria. Methods Women were stratified into 3 distinct groups according to their weight gain status: lost weight or gained less than 5 kg (Group 1, n=237 (31.4%)), gained 5-9kg (Group 2, n=77 (10.2%)) or gained >9kg (Group 3 n=440 (58.4%)). The groups were further subdivided according to treatment modality: diet alone (GDM-D) or diet and insulin (GDM-I). Main outcome measures Maternal (eg.preeclampsia, pregnancy induced hypertension (PIH)) and infant outcomes (eg.mortality, prematurity, macrosomia, large for gestational age (LGA)) were assessed. Results Women in Group 1 were older with a higher booking BMI compared to Groups 2 and 3. Logistic regression analysis adjusted for baseline BMI, insulin use, smoking status, parity, family history, ethnicity and age determined no significant difference in maternal or infant outcomes for women in Group1 compared to those in Group 2. Women with excessive weight gain had higher rates of PIH, macrosomia and LGA. Conclusion In our population, weight gain less than IOM guideline does not appear to be associated with adverse outcomes. However, further validation through a prospective study with a larger obese GDM cohort is required before these findings could be recommended for routine clinical use.